Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 25, 2024

Durvalumab Plus Chemoradiotherapy for Unresectable Stage III NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
Lung Cancer 2024 Mar 07;190(xx)107530, DW Kim, B Chul Cho, K Pachipala, SW Kim, CL Wang, GC Chang, MJ Ahn, R Alvarez, CH Chiu, J Trigo, A Estival, SD Karam, C O'Brien, H Gowda, H Jiang, JE Bauman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading